表面活性蛋白D多聚化及基因多态性在慢阻肺与哮喘中的研究
该研究在黎巴嫩慢阻肺和哮喘患者中检测血清SP-D多聚化形式与rs721917基因多态性,发现慢阻肺患者血清SP-D水平显著升高而哮喘患者不升高,Met11Thr变异影响SP-D水平及多聚化程度但与疾病无关联,Met11/Met11基因型患者HMW/LMW比值显著低于对照。
要点
- 慢阻肺患者血清SP-D水平显著升高,哮喘患者未见显著升高。
- Met11Thr变异强烈影响血清SP-D水平及多聚化程度,但与慢阻肺和哮喘无关联。
- Met11/Met11基因型慢阻肺和哮喘患者HMW/LMW血清SP-D比值显著低于对照。
核心结论
- 非多聚化形式的血清SP-D在慢阻肺和哮喘患者中占优势,提示肺部疾病中存在显著程度的SP-D降解。
- 能够分离SP-D蛋白水解产物或修饰形式与天然三聚体的检测方法可能为肺部炎症疾病提供更优标志物。
研究设计与样本
- 研究纳入88例慢阻肺患者、121例哮喘患者和223例对照,采用ELISA测定血清SP-D水平。
- 随机选取受试者进行rs721917基因分型,并通过凝胶渗透色谱分离高分子量(HMW)和低分子量(LMW)SP-D。
主要发现
- 与对照相比,慢阻肺患者血清SP-D水平显著升高,而哮喘患者未显著升高。
- Met11Thr变异强烈影响血清SP-D水平及多聚化程度,但与慢阻肺和哮喘均无关联。
- Met11/Met11基因型的慢阻肺和哮喘患者HMW/LMW血清SP-D比值显著低于对照。
临床怎么用
- 血清SP-D多聚化状态(HMW/LMW比值)可能有助于反映肺部疾病中的蛋白降解程度。
- 针对SP-D蛋白水解产物或修饰形式的检测方法有望成为肺部炎症疾病的优化标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: A structural single nucleotide polymorphism rs721917 in the surfactant protein D (SP-D) gene, known as Met11Thr, was reported to influence the circulating levels and degree of multimerization of SP-D and was associated with both COPD and atopy in asthma. Moreover, disease-related processes are known to degrade multimerized SP-D, however, the degree of the protein degradation in these diseases is not clarified. We aimed to determine the distribution of multimerized (high molecular weight (HMW)) and non-multimerized (low molecular weight (LMW)) species of serum SP-D and their correlation with genetic polymorphisms and presence of disease in Lebanese COPD and asthmatic patients. METHODS: Serum SP-D levels were measured by ELISA in 88 COPD, 121 asthmatic patients and 223 controls. Randomly selected subjects were chosen for genotyping of rs721917 and multimerization studies. HMW and LMW SP-D were separated by gel permeation chromatography. RESULTS: Serum SP-D levels were significantly increased in patients with COPD, but not in asthmatic patients, when compared to controls. Met11Thr variation strongly affected serum SP-D levels and the degree of multimerization, but was not associated with COPD and asthma in the study. Remarkably, HMW/LMW serum SP-D ratio was significantly lower in Met11/Met11 COPD and asthmatic patients compared to controls. CONCLUSION: Collectively, non-multimerized species of serum SP-D were dominant in COPD and asthmatic patients suggesting that degradation of SP-D takes place to a significant degree in pulmonary disease. Assays that can separate SP-D proteolytic breakdown products or modified forms from naturally occurring SP-D trimers may result in optimal disease markers for pulmonary inflammatory diseases.
引用
- Fakih D, Akiki Z, Junker K, et al. Surfactant protein D multimerization and gene polymorphism in COPD and asthma. Respirology. 2017. PMID: 28960651. doi:10.1111/resp.13193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。